Prevention Of Acute And Delayed Chemotherapy Induced Nausea And Vomiting Therapeutics

1. Aloxi patent expiration

Treatment: Prevention of postoperative nausea and vomiting; Prevention of chemotherapy-induced nausea and vomiting

ALOXI's oppositions filed in EPO
ALOXI IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9125905 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US8598219 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US8598219

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US5202333 HELSINN Tricyclic 5-HT3 receptor antagonists
Apr, 2015

(10 years ago)

US5202333

(Pediatric)

HELSINN Tricyclic 5-HT3 receptor antagonists
Oct, 2015

(10 years ago)

US9066980 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US8729094 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US9457021 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US7947725 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US7960424 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US8518981 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US9439854 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US8598218 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US9173942 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US9457020 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US7947724 HELSINN Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(2 years ago)

US7947724

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US7947725

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US7960424

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US8729094

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US8518981

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US8598218

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US9173942

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US9125905

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US9439854

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US9457020

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US9457021

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)

US9066980

(Pediatric)

HELSINN Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 6 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Aug 22, 2011
New Indication(I-684) May 27, 2017
M(M-136) May 27, 2017
Pediatric Exclusivity(PED) Nov 27, 2017

Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 29 February, 2008

Dosage: INJECTABLE; CAPSULE

How can I launch a generic of ALOXI before it's drug patent expiration?
More Information on Dosage

ALOXI family patents

Family Patents